Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Sarcoma 11Neoplasms 4Neoplasm Metastasis 2Leiomyosarcoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

pembrolizumab 156Gemcitabine 140Capecitabine 123Paclitaxel 120Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Leucovorin 97Docetaxel 97Cisplatin 89Radiosurgery 88Irinotecan 87Carboplatin 85Cetuximab 72Cyclophosphamide 71Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × olaratumab × Clear all
NCT02677116 2020-05-20

A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer

Eli Lilly and Company

Phase 1 Completed
68 enrolled 26 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01199822 2017-04-14

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Completed
16 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡